GOLDILOX-TIMI 69 is a Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of MEDI6570 (a fully human monoclonal antibody against LOX-1) in Participants with a Prior Myocardial Infarction, Persistent Inflammation, and Elevated N-Terminal Prohormone Brain Natriuretic Peptide. MAIN RESULTS: Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a … Continue reading GOLDILOX-TIMI 69